A common SCN5A variant alters the responsiveness of human sodium channels to class I antiarrhythmic agents

Journal of Cardiovascular Electrophysiology

Volumn 18, Issue 4, 2007, Pages 434-440

  Shuraih, Mossaab ^a   Ai, Tomohiko ^a   Vatta, Matteo ^b,e   Sohma, Yoshiro ^c,d   Merkle, Eileen M ^b   Taylor, Erica ^b   Li, Zhaohui ^b   Xi, Yutao ^a   Razavi, Mehdi ^a   Towbin, Jeffrey A ^b   Cheng, Jie ^a,e  

^a ST LUKE S EPISCOPAL HOSPITAL   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c OSAKA MEDICAL COLLEGE   (Japan)

^d UNIVERSITY OF MISSOURI   (United States)

^e TEXAS HEART INSTITUTE   (United States)

Author keywords

Patch clamp; Pharmacology; Polymorphism; SCN5A; Sodium channel

Indexed keywords

FLECAINIDE; MEXILETINE; QUINIDINE; SODIUM CHANNEL NAV1.5; UNCLASSIFIED DRUG; VOLTAGE GATED SODIUM CHANNEL;

ANTIARRHYTHMIC ACTIVITY; ARTICLE; CELL STRAIN HEK293; CHANNEL GATING; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ACTIVITY; EMBRYO; GENETIC VARIABILITY; HUMAN; HUMAN CELL; PATCH CLAMP; PRIORITY JOURNAL; PULSE RATE; SINGLE NUCLEOTIDE POLYMORPHISM; SODIUM CURRENT; TEMPERATURE DEPENDENCE; WHOLE CELL; WILD TYPE;

ANTI-ARRHYTHMIA AGENTS; CELLS, CULTURED; FLECAINIDE; HUMANS; ION CHANNEL GATING; MEXILETINE; MUSCLE PROTEINS; PATCH-CLAMP TECHNIQUES; QUINIDINE; SODIUM CHANNELS; VARIATION (GENETICS);

EID: 33947259522     PISSN: 10453873     EISSN: 15408167     Source Type: Journal    
DOI: 10.1111/j.1540-8167.2007.00777.x     Document Type: Article

References (18)

1. Chen Q, Kirsch GE, Zhang D, Brugada R, Brugada J, Brugada P, Potenza D, Moya A, Borggrefe M, Breithardt G, Oritz-Lopez R, Wang Z, Antzelvitch C, O'Brien RE, Schulze-Bahr E, Keating MT, Towbin JA, Wang Q: Genetic basis and molecular mechanism for idiopathic ventricular fibrillation. Nature 1998;392:293-296.
2. Wang Q, Shen J, Splawski I, Atkinson D, Li Z, Robinson JL, Moss AJ, Towbin JA, Keating MT: SCN5A mutations associated with an inherited cardiac arrhythmia, long QT syndrome. Cell 1995;80:805-811.
3. Vatta M, Dumaine R, Varghese G, Richard TA, Shimizu W, Aihara N, Nademanee K, Brugada R, Brugada J, Veerakul G, Li H, Bowles NE, Brugada P, Antzelvitch C, Towbin JA: Genetic and biophysical basis of sudden unexplained nocturnal death syndrome (SUNDS), a disease allelic to Brugada syndrome. Hum Mol Genet 2002;11:337-345.
4. Nattel S, Kneller J, Zou R, Leon LJ: Mechanisms of termination of atrial fibrillation by Class I antiarrhythmic drugs: Evidence from clinical, experimental, and mathematical modeling studies. J Cardiovasc Electrophysiol 2003;14:S133-S139.
5. Wolpert C, Echternach C, Veltmann C, Antzelevitch C, Thomas GP, Spehl S, Streitner F, Kuschyk J, Schimpf R, Haase KK, Borggrefe M: Intravenous drug challenge using flecainide and ajmaline in patients with Brugada syndrome. Heart Rhythm 2005;2:254-260.
6. Nattel S: Are all sodium channel blockers created equal? Clinical-basic correlations based on observations in Brugada syndrome. Heart Rhythm 2005;2:261-262.
7. Splawski I, Timothy KW, Tateyama M, Clancy CE, Malhotra A, Beggs AH, Cappuccio FP, Sagnella GA, Kass RS, Keating MT: Variant of SCN5A sodium channel implicated in risk of cardiac arrhythmia. Science 2002;297:1333-1336.
8. Viswanathan PC, Benson, DW, Balser JR: A common SCN5A polymorphism modulates the biophysical effects of an SCN5A mutation. J Clin Invest 2003;111:341-346.
9. Makielski JC, Ye B, Valdivia CR, Pagel MD, Pu J, Tester DJ, Ackerman MJ: A ubiquitous splice variant and a common polymorphism affect heterologous expression of recombinant human SCN5A heart sodium channels. Circ Res 2003;93:821-828.
10. Burke A, Creighton W, Mont E, Li L, Hogan S, Kutys R, Fowler D, Virmani R: Role of SCN5A Y1102 polymorphism in sudden cardiac death in blacks. Circulation 2005;112:798-802.
11. Ackerman MJ, Splawski I, Makielski JC, Tester DJ,Will ML, Timothy KW, Keating MT, Jones G, Chadha M, Burrow CR, Stephens JC, Xu C, Judson R, Curran ME: Spectrum and prevalence of cardiac sodium channel variants among black, white, Asian, and Hispanic individuals: Implications for arrhythmogenic susceptibility and Brugada/long QT syndrome genetic testing. Heart Rhythm 2004;1:600-607.
12. Tan BH, Valdivia CR, Rok BA, Ye B, Ruwaldt KM, Tester DJ, Ackerman MJ, Makielski JC: Common human SCN5A polymorphisms have altered electrophysiology when expressed in Q1077 splice variants. Heart Rhythm 2005;2:741-747.
13. Courtney KR: Mechanism of frequency-dependent inhibition of sodium currents in frog myelinated nerve by the lidocaine derivative GEA. J Pharmacol Exp Ther 1975;195:225-236.
14. Ramos E, O'leary ME: State-dependent trapping of flecainide in the cardiac sodium channel. J Physiol 2004;560:37-49.
15. Ragsdale DS, McPhee JC, Scheuer T, Catterall WA: Molecular determinants of state-dependent block of Na+ channels by local anesthetics. Science 1994;265:1724-1728.
16. Ragsdale DS, McPhee JC, Scheuer T, Catterall WA: Common molecular determinants of local anesthetic, antiarrhythmic, and anticonvulsant block of voltage-gated Na+ channels. Proc Natl Acad Sci USA 1996;93:9270-9275.
17. Nau C,Wang S-Y, Strichartz GR, Wang GK: Point mutations at N434 in D1-S6 of mu1 Na(+) channels modulate binding affinity and stereoselectivity of local anesthetic enantiomers. Mol Pharmacol 1999;56:404-413.
18. Hille B: Local anesthetics: Hydrophilic and hydrophobic pathways for the drug-receptor reaction. J Gen Physiol 1977;69:497-515.